TheraVitae Ltd. Report issue

For profit Phase 1 Phase 2
Founded: Toronto Canada (2003)
Status: Acquired by Technical Ventures RX Corp (2013)

Organization Overview

First Clinical Trial
2006
NCT00523224
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

Key: TheraVitae Ltd. (0) Acquired (1)

autologous angiogenic cell precursors (1 trial)

Drugs in Phase 1 Trials (1)

Key: TheraVitae Ltd. (0) Acquired (1)

angiogenic cell precursors (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Heart Failure (Phase 1)

Ischemia (Phase 2)

Peripheral Arterial Disease (Phase 2)

Overview

  • Highest Phase: None
  • # of Trials: 2
  • # of Trial APIs: 2